Kexing Biopharm Co., Ltd. Class A 688136
SSE · China · Health Technology
CNY 24.27+0.70 (+2.97%)
Market closed· · CNY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · CNY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
San Diego, California--(Newsfile Corp. - June 29, 2026) - Recently, the Head of Global Business Development at Kexing Biopharm Co., Ltd. (hereinafter referred to as "Kexing Biopharm", 688136.SH) was invited to attend the 2026 BFC-Cytiva Global Healthcare Summer BD & Investment Conference. She delivered a roadshow speech showcasing the Company's innovative pipeline in autoimmune diseases, oncology, and ophthalmology to the global pharmaceutical and investment communities, highlighting the latest.
From June 16 to 18, the CPHI & PMEC China 2026 was held at the Shanghai New International Expo Center. Kexing Biopharm (688136.SH) showcased multiple self-developed innovative drug pipelines and over 30 products for international markets at the exhibition. The company was also invited to attend the CPHI Award ceremony and received the R&D Innovation Award for its achievements in innovation and international development.
Earlier this week, IQVIA Holdings announced an expanded collaboration with Kexing Biopharm to support a global, multi-product biosimilar development and commercialization program using its AI-enabled clinical trial capabilities across design, site selection and execution. This partnership highlights how IQVIA is using integrated data, analytics and clinical expertise to help biopharma clients execute complex international biosimilar strategies under a single coordinated framework. Next,...
BioDlink announced the first international shipment of its bevacizumab injection biosimilar to Colombia in partnership with Kexing BioPharm. Both companies marked this milestone with a special ceremony when specially-decorated transport vehicles arrived.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.